Prof Dr. Yinyuan Ding | Tumorigenesis | Best Researcher Award

Posted on by Pencis

Prof Dr. Yinyuan Ding | Tumorigenesis | Best Researcher Award

Chongqing Medical University | China

Author Profile

Scopus

ORCID ID

Professor Yinyuan Ding

🌟 Professor of Oncology
🏥 Chongqing Medical University

🎓 Academic and Professional Background:

Professor Yinyuan Ding obtained a Ph.D. from Peking University in 2011 and pursued postdoctoral training at UT Southwestern Medical Center, where he was later promoted to Assistant Professor in 2018. In 2019, he returned to China and joined Chongqing Medical University as a professor. His research explores tumorigenesis and glucolipid metabolic disorders, focusing on the LRP1 receptor’s role in liver and vascular signaling, with implications for novel treatments for Hepatocellular Carcinoma (HCC) and Metabolic Associated Steatohepatitis-Liver Disease (MASLD).

🔬 Research and Innovations:

  • Principal Investigator
    2023-2026: “The role of LRP1 in hepatic glucose metabolism and HCC progression” (National Natural Science Foundation of China)
    2021: “The role of Asprosin in hepatocellular carcinoma” (Chongqing Municipal Human Resources Bureau)

 

  • Participant
    2015-2020: “VLDL and ApoE receptors metabolism” (NIH-NHLBI)
    2011-2015: “Cell signaling and cholesterol-lipoprotein receptors” (NIH)

📚 Journals Published:

Advanced Science, Elife, Science Signaling, EBioMedicine, JBC

🤝 Collaborations:

Collaborates with Joachim Herz (UT Southwestern Medical Center, USA)

👥 Professional Memberships:

Director of the China Branch, International Atherosclerosis Society

🧬 Areas of Research:

  • Oncology
  • Tumorigenesis
  • Hepatology
  • Lipoprotein & Lipid Research

📝 Contributions:

Professor Ding’s groundbreaking research on LRP1 has revealed its multifaceted roles in regulating cholesterol and glucose metabolism. His work identified a critical mechanism by which LRP1 affects hepatic insulin resistance, dyslipidemia, and HCC progression. This novel insight into LRP1’s function opens pathways for innovative therapeutic strategies for cancer and metabolic disorders.

✨Conclusion:

In summary, Professor Yinyuan Ding is a distinguished expert in oncology and hepatology, with a strong focus on the molecular mechanisms of tumorigenesis and lipid metabolism disorders. His innovative research on LRP1 has led to significant breakthroughs in understanding liver disease and cancer progression, paving the way for novel therapeutic strategies. With a wealth of experience from top institutions and numerous prestigious publications and patents, Professor Ding continues to make impactful contributions to the field of cancer research, driving advancements in both basic science and clinical applications. 🌟

📊🔬NOTABLE PUBLICATION:

1. LRP1 facilitates hepatic glycogenesis by improving the insulin signaling pathway in HFD-fed mice

  • Authors: Guo, X., Pu, J., Tang, Z., Liu, T., Ding, Y.
  • Journal: Animal Models and Experimental Medicine
  • Year: 2024

2. Erratum: Correction: LRP1 integrates murine macrophage cholesterol homeostasis and inflammatory responses in atherosclerosis

  • Authors: Xian, X., Ding, Y., Dieckmann, M., Tsai, S., Herz, J.
  • Journal: eLife
  • Year: 2017 (Erratum published in 2024)

3. Loss of LRP1 Promotes Hepatocellular Carcinoma Progression via UFL1-Mediated Activation of NF-κB Signaling

  • Authors: Guo, X., Yang, F., Liu, T., Herz, J., Ding, Y.
  • Journal: Advanced Science
  • Year: 2024